NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NAN

NAN - NANOSONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.58
Index: ASX200 | ASX300 | ALL-ORDS

Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.26

20 Feb
2025

0.800

OPEN

$3.65

23.12%

HIGH

$4.29

2,780,935

LOW

$3.65

TARGET
$3.987 -6.4% downside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
NAN: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 4.3 5.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx - 35.2% 32.4% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 79.8 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx4.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx171.6 M
Book Value Per Share xxxxxxxxxxxxxxx60.1
Net Operating Cash Flow xxxxxxxxxxxxxxx22.8 M
Net Profit Margin xxxxxxxxxxxxxxx7.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx7.50 %
Return on Invested Capital xxxxxxxxxxxxxxx7.21 %
Return on Assets xxxxxxxxxxxxxxx5.54 %
Return on Equity xxxxxxxxxxxxxxx7.50 %
Return on Total Capital xxxxxxxxxxxxxxx4.58 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx20.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx6 M
Total Debt xxxxxxxxxxxxxxx9 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx130 M
Price To Book Value xxxxxxxxxxxxxxx4.97

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx2.5 M
Capex % of Sales xxxxxxxxxxxxxxx1.47 %
Cost of Goods Sold xxxxxxxxxxxxxxx44 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx119 M
Research & Development xxxxxxxxxxxxxxx30 M
Investments - Total xxxxxxxxxxxxxxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

21/02/2025

3

Hold

$4.06

-4.69%

Nanosonics' 1H25 revenues (pre-released) increased 18% off a weak prior period result. In the US, revenues increased by 17% versus 1H24 and 3% versus 2H24, with the latter measure being the better gauge for overall performance in Bell Potter's view.

Relative to 1H24, capital sales of the Trophon device increased by 11%. Consumables revenues increased by 19% year on year in
line with growth of the installed based including a 7% increase in cycles completed.

The FY26 forecast is for earnings to decline as opex increases to support a product launch for CORIS. In the very short term, Bell Potter notes, the outlook remains positive due to earnings upgrades and ahead of a new product approval for CORIS on the horizon.

Target rises to $4.06 from $3.45, Hold retained.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 6.40 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 5.50 cents.

Citi

xx/xx/xxxx

3

xxxxxxx xx xxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

02/09/2024

1

Overweight

$4.00

-6.10%

Wilsons continues to remind investors, the approval of CORIS FDA would lift the target price on Nanosonics to $6.33 with the possible approval April next year.

Regarding FY24 results most of the financials were pre-released. The analyst highlights a recovery in 2H capital sales ex APAC and a notable increase in service revenue where there is robust upgrade activity.

The company has $130m in net cash and is well funded to launch CORIS, increase Trophon franchise growth and possibly undertake M&A.

The Overweight rating is maintained with a $4 target.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 3.20 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of 3.90 cents.
Access Extra Coverage Research History >

NAN STOCK CHART

FNArena News on NAN

1
FNArena Corporate Results Monitor – 22-02-2025

2:00 PM - Australia
2
Australian Broker Call *Extra* Edition – Jan 28, 2025

Jan 28 2025 - Daily Market Reports
3
Weekly Ratings, Targets, Forecast Changes – 24-01-25

Jan 28 2025 - Weekly Reports
4
Weekly Ratings, Targets, Forecast Changes – 17-01-25

Jan 20 2025 - Weekly Reports
5
Rudi’s View: Banks, Miners & Quality Small Caps

Sep 26 2024 - Rudi's View

Latest Medical Equipment & Devices News

1
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
2
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
3
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
4
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
5
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
6
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
7
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
8
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
9
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
10
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps